- Home
- MASS vs NBTX Comparison
MASS vs NBTX Comparison
Compare MASS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASS
- NBTX
- Stock Information
- Founded
- MASS 2012
- NBTX 2003
- Country
- MASS United States
- NBTX France
- Employees
- MASS N/A
- NBTX N/A
- Industry
- MASS Medical/Dental Instruments
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- MASS Health Care
- NBTX Health Care
- Exchange
- MASS Nasdaq
- NBTX Nasdaq
- Market Cap
- MASS 235.8M
- NBTX 211.9M
- IPO Year
- MASS 2020
- NBTX 2020
- Fundamental
- Price
- MASS $5.44
- NBTX $8.70
- Analyst Decision
- MASS Strong Buy
- NBTX Strong Buy
- Analyst Count
- MASS 3
- NBTX 1
- Target Price
- MASS $8.00
- NBTX $8.00
- AVG Volume (30 Days)
- MASS 248.3K
- NBTX 16.0K
- Earning Date
- MASS 08-05-2025
- NBTX 09-18-2025
- Dividend Yield
- MASS N/A
- NBTX N/A
- EPS Growth
- MASS N/A
- NBTX N/A
- EPS
- MASS N/A
- NBTX N/A
- Revenue
- MASS $65,560,000.00
- NBTX N/A
- Revenue This Year
- MASS N/A
- NBTX N/A
- Revenue Next Year
- MASS $21.68
- NBTX $74.67
- P/E Ratio
- MASS N/A
- NBTX N/A
- Revenue Growth
- MASS 37.93
- NBTX N/A
- 52 Week Low
- MASS $1.81
- NBTX $2.76
- 52 Week High
- MASS $8.06
- NBTX $10.59
- Technical
- Relative Strength Index (RSI)
- MASS 32.11
- NBTX 56.10
- Support Level
- MASS $5.32
- NBTX $8.03
- Resistance Level
- MASS $6.32
- NBTX $9.14
- Average True Range (ATR)
- MASS 0.31
- NBTX 0.54
- MACD
- MASS -0.09
- NBTX -0.16
- Stochastic Oscillator
- MASS 8.82
- NBTX 26.17
About MASS 908 Devices Inc.
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.